Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,364
  • Shares Outstanding, K 26,014
  • Annual Sales, $ 170 K
  • Annual Income, $ -18,110 K
  • 60-Month Beta 0.06
  • Price/Sales 695.35
  • Price/Cash Flow N/A
  • Price/Book 6.00
Trade FENC with:

Options Overview Details

View History
  • Implied Volatility 110.72% ( -27.12%)
  • Historical Volatility 48.41%
  • IV Percentile 61%
  • IV Rank 41.65%
  • IV High 265.49% on 01/03/22
  • IV Low 0.25% on 03/10/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 173
  • Open Int (30-Day) 192

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 3.52
  • Number of Estimates 1
  • High Estimate 3.52
  • Low Estimate 3.52
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +2,807.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.11 +10.71%
on 01/24/22
4.83 -5.76%
on 01/12/22
+0.06 (+1.34%)
since 12/23/21
3-Month
3.82 +19.05%
on 12/01/21
5.20 -12.50%
on 11/29/21
+0.17 (+3.88%)
since 10/22/21
52-Week
2.90 +56.90%
on 05/11/21
5.20 -12.50%
on 11/29/21
+0.47 (+11.52%)
since 01/22/21

Most Recent Stories

More News
Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down

Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.

SRPT : 66.52 (-1.16%)
VKTX : 3.55 (-0.28%)
EDIT : 18.48 (+1.82%)
FENC : 4.55 (+3.64%)
Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it...

FRX.TO : 5.39 (-7.55%)
FENC : 4.55 (+3.64%)
Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable

Adherex Technologies Inc. (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made...

FENC : 4.55 (+3.64%)
Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK Approval...

FRX.TO : 5.39 (-7.55%)
FENC : 4.55 (+3.64%)
Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ If Approved by the FDA, PEDMARK™ Stands to Be the First...

FRX.TO : 5.39 (-7.55%)
FENC : 4.55 (+3.64%)
4 Breakout Stocks for Impressive Returns

SB, VTSI, FENC and APYX qualified the screen for breakout stocks for today.

SB : 3.30 (+0.30%)
FENC : 4.55 (+3.64%)
VTSI : 6.30 (+0.80%)
APYX : 11.08 (+5.62%)
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique...

FRX.TO : 5.39 (-7.55%)
FENC : 4.55 (+3.64%)
Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~

FRX.TO : 5.39 (-7.55%)
FENC : 4.55 (+3.64%)
Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...

FENC : 4.55 (+3.64%)
FRX.TO : 5.39 (-7.55%)
Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility

RESEARCH TRIANGLE PARK, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique...

FRX.TO : 5.39 (-7.55%)
FENC : 4.55 (+3.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 5.22
2nd Resistance Point 4.91
1st Resistance Point 4.73
Last Price 4.55
1st Support Level 4.24
2nd Support Level 3.93
3rd Support Level 3.75

See More

52-Week High 5.20
Last Price 4.55
Fibonacci 61.8% 4.32
Fibonacci 50% 4.05
Fibonacci 38.2% 3.78
52-Week Low 2.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar